The extracellular tumor microenvironment is acidified, whereas the intracellular pH of tumor and stromal cells is neutral. cis-Urocanic acid (cis-UCA), an endogenous compound of the skin, can acidify the cytosol by transporting protons into the cells. This phenomenon, termed the protodynamic concept, was studied here in human cancer cells. cis-UCA dose-dependently reduced the number of viable human melanoma, cervical carcinoma, and fibrosarcoma cells at weakly acidic extracellular pH. The intracellular pH decreased by up to 0.5 pH units in a concentration-dependent manner with 0.3-30 mM cis-UCA at extracellular pH 6.5 but not at pH 7.4. Under the same conditions, 30 mM cis-UCA induced annexin-V binding and activation of caspase-3 in A2058 melanoma cells as signs of apoptotic cell death. Finally, growth of human melanoma xenografts in SCID mice was suppressed by 60% following intratumoral injection of cis-UCA. Accordingly, the percentage of tumor necrosis and active caspase-3-immunopositive cells increased, whereas proliferation activity decreased. These results identify cis-UCA as an anticancer agent inhibiting melanoma growth by immediate intracellular acidification followed by apoptotic cell death in vivo.
INTRODUCTION
Urocanic acid (UCA; 3-(1H-imidazol-4-yl)prop-2-enoic acid) is an endogenous compound in the mammalian skin. trans-UCA, synthesized enzymatically from histidine and located in the upper epidermis, is photo-isomerized to cis-UCA by exposure to UV radiation. It has been well documented that cis-UCA is able to induce immunosuppression (De Fabo and Noonan, 1983; Norval and El-Ghorr, 2002) . This may involve cellular signaling activated through the 5-HT 2A receptor (Walterscheid et al., 2006) , although this view has recently been challenged (Woodward et al., 2006; Kaneko et al., 2009) . The endogenous concentrations of UCA in human skin, calculated considering the mean thickness of the epidermis, extend over the range 0.5-8.9 mM (Laihia et al., 1998) . It is plausible that these concentrations have an effect on maintaining the innate antibacterial, antiproliferative, and anti-inflammatory environment in the epidermal layer of human skin (''acid mantle''; Schade and Marchionini, 1928) . Accordingly, UCA has been proposed as the major acid-base regulator in the epidermis (Krien and Kermici, 2000) .
Many cellular functions in both normal and transformed cells are regulated by intracellular pH (pH i ). Intracellular acidification modulates the proliferation of cancer cells (Thangaraju et al., 1999; Cosentini et al., 2001; Wahl et al., 2002) and promotes apoptosis (Gottlieb et al., 1996; . pH below neutral may also have a positive effect on the uptake and antiproliferative activity of some pharmacological compounds (Jahde et al., 1989; Atema et al., 1993; Gabr et al., 1997; Wahl et al., 2002) . We have observed that cis-UCA has the ability to penetrate into cells and acidify the cytoplasm by transporting a proton from the weakly acidic extracellular environment to the neutral or weakly alkaline intracellular compartment, resulting in inhibition of the proliferation of urinary bladder cancer cells (Laihia et al., 2009) . The acid dissociation properties of cis-UCA facilitate the transportation and release of one of the imidazolyl protons into the cytosol (Juusola et al., 2007) . We have termed this action as the protodynamic concept (Laihia et al., 2009) . Because the proton transport is a stoichiometric reaction, that is each cis-UCA molecule carries one proton and releases it inside the cell, the molar concentrations of cis-UCA must be substantially higher than when using conventional anticancer agents. The purpose of this study was to test the protodynamic concept in cancer cells of human origin in culture and in solid tumor xenografts in mice with cis-UCA in a weakly acidic aqueous vehicle. The results identify cis-UCA as an anticancer agent capable of promoting melanoma cell apoptosis and inhibiting tumor outgrowth by immediate intracellular acidification and subsequent induction of programmed cell death.
RESULTS
Inhibition of cancer cell proliferation by cis-UCA at mildly acidic extracellular pH cis-UCA dose dependently reduced the number of viable human metastatic melanoma (A2058), cervical carcinoma (HeLa), and fibrosarcoma (HT-1080) cells when tested at extracellular pH 6.5 (Figure 1a) . The IC 50 concentrations were 8.4-20 mM cis-UCA in the three cell lines. To show that the protodynamic concept is functional only in a mildly acidic extracellular milieu typically at about pHo6.7, the A2058 cells were first cultured for 3 days at pH 7.3 in the absence of cis-UCA and then for 44 hours either at pH 7.4 or pH 6.5 with or without 10 mM cis-UCA. cis-UCA significantly (P ¼ 0.0000032) reduced the number of viable A2058 cells at pH 6.5 (31% inhibition) but negligibly at pH 7.4 (3% inhibition) (Figure 1b) . To examine whether an extracellular pH below neutral affects cell viability per se or sensitivity to cis-UCA, A2058 cells were first cultured at pH 6.7 for 3 days and then at pH 6.5 with or without 10 mM cis-UCA for 44 hours. As shown in Figure 1b , the mildly acidic medium had no effect on cell viability in the absence of cis-UCA, whereas the response to cis-UCA was comparable to that seen in cells pre-cultured at pH 7.3 (28% inhibition; P ¼ 0.0000017). Essentially similar results were obtained with HeLa and HT-1080 cells (data not shown). Finally, the ability of cancer cells to recover from the antiproliferative effect of cis-UCA treatment was tested. A2058 cells were first cultured with 10 and 30 mM cis-UCA for 20 hours at pH 6.5, followed by a recovery culture in the absence of cis-UCA for 44 hours in the same medium. After the 20-hour incubation with cis-UCA, the number of viable cells was reduced by 39% (P ¼ 0.021) and 74% (P ¼ 0.00061) with 10 and 30 mM cis-UCA, respectively, as compared with viability in the absence of cis-UCA. A subsequent incubation of the same number of trypan blue-negative (viable) cells without cis-UCA for 44 hours restored the proliferation activity of cells pretreated with 10 mM cis-UCA. However, the proliferation of cells pretreated with 30 mM cis-UCA remained significantly suppressed (69% inhibition; P ¼ 0.000018) (Figure 1c) . The results show that the cancer cells can recover from the suppressed state after treatment with 10 mM but not after treatment with 30 mM cis-UCA in about 2 days.
Intracellular acidification caused by cis-UCA Flow cytometric analysis of intracellular pH (Supplementary Methods online) in A2058 melanoma cells showed that the pH i decreased in a dose-dependent manner with 0.3-30 mM cis-UCA in an extracellular buffer adjusted to pH 6.5, reaching a decrease of about 0.5 pH units with 30 mM cis-UCA (Figure 1d ). By contrast, the change in pH i remained in the range of 0.1-0.18 pH units with the same cis-UCA concentrations at the extracellular pH 7.4 and with trans-UCA at both pH levels. The change in extracellular pH from 7.4 to 6.5 without UCA caused a decrease in pH i by 0.1 units ( Figure 1d ). To our knowledge it is previously unreported that cis-UCA is capable of acidifying the cytosol of cancer cells.
Induction of melanoma cell apoptosis by cis-UCA
Signs of early apoptosis were analyzed by annexin-V binding to the cell membrane. Camptothecin (CPT) was used as a positive control, which at a concentration of 0.8 mM suppressed 88% of A2058 melanoma cell proliferation in a 2-day assay (Figure 2a ). After an 18-hour treatment with 30 mM cis-UCA at an acidic extracellular pH of 6.5, 33% of the cells bound to annexin-V, compared with 7% in the control incubation, 18% with trans-UCA, and 81% with www.jidonline.org 2433 10 mM CPT. At pH 7.4, only 25% of the cells were annexin-Vpositive with 30 mM cis-UCA and 13% with trans-UCA treatment ( Figure 2b ). Incubation of the A2058 cells with increasing concentrations of cis-UCA at pH 6.5 for 24 hours resulted in a dramatic induction of caspase-3-like enzyme activity (Supplementary Methods online) with 30 mM cis-UCA but not with any of the lower concentrations studied ( Figure  2c ). Western blotting analysis confirmed the presence of the active caspase-3 protein in cell lysates at 24 hours but not at 3 or 6 hours of incubation with 30 mM cis-UCA (Figure 2d ). Several experiments were performed to characterize the dependence of caspase-3 activation on the duration of the incubation. Caspase-3-like activity was induced only when the cells were treated with 30 mM cis-UCA at pH 6.5 for more than 6 hours ( Figure 2e ). The cis-UCA-induced caspase-3-like activity at pH 6.5 exceeded (Po0.001) the spontaneous induction of activity observed at 30 and 36 hours of continuous culture in the absence of cis-UCA (Figure 2e ). Cell viability determined as the number of trypan bluenegative cells compared with control incubation reduced gradually to below the 20% level at 36 hours with 30 mM cis-UCA at pH 6.5 (Figure 2f ). At pH 7.4, the viability with 30 mM cis-UCA treatment approached the 50% level (Figure 2f ). This may be partially due to spontaneous acidification of the medium after 18 hours of incubation, producing a difference of no greater than about 0.5 pH units between the cis-UCA treatments initially adjusted to pH 6.5 and 7.4 (Figure 2g ).
Suppression of human melanoma xenograft growth by cis-UCA in mouse in vivo
The concept of local protodynamic treatment of solid tumors with cis-UCA was tested in an in vivo xenograft tumor model established with human A2058 melanoma cells injected in the skin of severe combined immunodeficient (SCID)/SCID mice. The 1-mM concentration of CPT (Figure 2a) was chosen for the xenograft study. At day 16 after initiating the intratumoral treatments, the mean relative tumor area was 56% smaller (P ¼ 0.027) in animals treated with 30 mM cis-UCA in comparison with that in the control group (Figure 3a) . The corresponding reduction in the tumor weight was 58% (Figure 3b ). The effect of cis-UCA approximately equaled that of CPT (Figure 3a and b) . The overall inhibition of tumor growth by weight was 61% (Po0.05 at days 7-16) with cis-UCA (Supplementary Table S1 online). No adverse local skin or tissue reactions, or systemic complications, were observed with any of the treatments.
In histological analysis, the untreated control tumors showed the morphology of a typical metastasis of melanoma. The nodule-shaped tumors showed marked nuclear atypia, high proliferative activity, thin fibrous septa, and small vascular structures. In addition, the tumors contained necrotic areas and there were few inflammatory cells at the border of the tumors. The xenograft thus serves well as a model for invasive and metastatic human melanoma. All tumors analyzed contained both vital and necrotic areas, the latter being more pronounced in the cis-UCA-treated animals ( Figure 4a ). The percentage of necrotic tissue was 24% in the control tumors and 41% in the cis-UCA group (Figure 4c and Supplementary Table S1 online). This difference was not statistically significant (P40.05). Immunohistochemical staining (Supplementary Methods online) showed cells positive for active (cleaved) caspase-3 at the border of the necrotic areas whereas the vital areas were typically negative (Figure 4a ). More active caspase-3 immunopositive cells were detected in the tumors in the cis-UCA group where the signs of both apoptosis and necrosis increased. The number of proliferating (Ki-67-positive) cells was reduced from a level of 68% in the control group to a 50% level in the cis-UCA group (P ¼ 0.023) (Figure 4b and d, and Supplementary Table S1 online). In conclusion, the results show that cis-UCA suppresses melanoma growth by promoting apoptotic cell death and by inhibiting cell proliferation in vivo.
DISCUSSION
Maintenance of pH i is a prerequisite for normal cell function. Cancer cells in a solid tumor tissue tend to form a pH gradient across the cell membrane; the cytosolic pH is maintained at a neutral or weakly alkaline pH, whereas the extracellular 6 A2058 cells in the back of SCID mice and allowed to grow for 2 weeks. The tumors were then injected with 50 ml cis-UCA (30 mM), CPT (1 mM), or PBS (control) three times a week. Development of (a) tumor area and (b) tumor weight were then followed (mean, SD). The data points have been normalized to unity in tumor sizes at day 0 (n ¼ 5 in each group).
microenvironment becomes weakly acidic, usually around pH 6.7 (Yamagata and Tannock, 1996; Kozin et al., 2001) . The acidification of the extracellular fluid in tumor tissue is a result of both enhanced glycolytic metabolism and poor tumor blood flow. The secreted lactate and other acidic metabolites remain largely in the tumor tissue and make the microenvironment weakly acidic. In this study we have tested the protodynamic concept in which protons are carried into cells by the cell-permeable organic acid cis-UCA. et al., 2002) . The results of this study show that cis-UCA is capable of causing intracellular acidification, resulting in inhibition of cell proliferation, induction of apoptosis in melanoma cells in vitro and in vivo, and in suppression of tumor growth in a xenograft model in vivo. To our knowledge this is previously unreported. We postulate that the mode of action is based on the favorable physicochemical properties of cis-UCA; the molecular structure possesses a biologically ''active'' proton-binding site in the imidazolyl ring (pK a2 ¼ 6.65-7.0; Roberts et al., 1982; Zimmerman et al., 1991; Juusola et al., 2007) , which, according to basic acid-base chemistry, remains mainly protonated at pH o7, that is in the pH milieu of the extracellular space of a solid tumor ( Figure 5 ). By contrast, trans-UCA, with its pK a of 5.8-6.1 (Roberts et al., 1982; Zimmerman et al., 1991; Juusola et al., 2007) , is mainly deprotonated both at pH 6.5 and pH 7.4, and thus cannot acidify the cells (Figure 1d ). In the protonated form cis-UCA is also electroneutral, which facilitates its penetration through the plasma membrane.
When inside the cancer cell, the cytosolic pH (7.2-7.4) favors the deprotonation of the cis-UCA molecules. Consequently, the imidazolyl proton is released, which results in increased acid load inside the cell ( Figure 5 ). This process is enzymeand receptor-independent, and therefore not interfered by the known mechanisms of resistance in cancer cells. Acidification of the cytosol is able to activate an apoptotic cellular signaling cascade (Gottlieb et al., 1996; within an optimal pH i range of 6.3-6.8 (Thangaraju et al., 1999; Matsuyama and Reed, 2000; . The present results show that treatment of the cells with cis-UCA in a weakly acidic buffer brings the pH i into this crucial pH range (Figure 1d ). In contrast to acidification observed upon activation of the death receptor-dependent extrinsic pathway of apoptosis, the decrease in pH caused by the mitochondria-dependent intrinsic pathway seems to be caspase-independent. Alterations in membrane proteins or their complexes that normally regulate the pH i have been suggested to be responsible for acidification in response to activation of the extrinsic cascade (Thangaraju et al., 1999; Lang et al., 2000) . Intracellular acidification may not be the initial trigger but rather a means of enhancement, as apoptosis is also known to commence without marked cytoplasmic acidification Lagadic-Gossmann et al., 2004) . Identification of these mechanisms in the cis-UCA-dependent intracellular acidification warrants further experimental efforts.
The results of the study indicate that both the cis-UCA concentration and exposure time are crucial for cellular effects. Accordingly, cis-UCA concentrations above 3 mM can produce measurable inhibition of cell proliferation (Figure 1a) , whereas the 30-mM but not the 10-mM concentration induces caspase-3 (Figure 2c ) at time points when the surviving cells can no more recover their initial proliferation activity (Figure 1c ). This may reflect the effect of sustained intracellular acidification, although the pH i was not measured in this study after longer treatments with cis-UCA. The need for a sufficiently high local concentration determines also the usage of cis-UCA in vivo. The intratumoral injection was used as a mode of delivery to achieve sufficiently high concentrations of cis-UCA within the tumor tissue.
The induction of apoptosis was verified in this investigation by measuring annexin-V binding and caspase-3-like enzyme activity in vitro and by determining the presence of the cleaved (active) form of caspase-3 both in vitro and in histological sections from tumors. The increased apoptosis observed by using these end points can be regarded as an indication that cis-UCA is able to induce a cellular process that can neither be explained only as a consequence of a cytotoxic effect nor as a transient cell-cycle arrest. The fact that the A2058 melanoma cells almost fully recovered from a treatment with 10 mM cis-UCA for 20 hours (Figure 1c) suggests that the cells can resist the pH i change caused by this concentration for a limited time period. When the incubation time is extended, viability clearly decreases (Figure 1a and b) . When apoptosis is induced with a higher concentration of cis-UCA up to the point of caspase-3 activation (Figure 2b-e) , the ability to proliferate is decreased permanently (Figure 1c) . In support of this observation, we have recently shown that the effective treatment time causing a decrease in viability can be considerably shortened in carcinoma cell lines from the human urinary bladder by increasing the cis-UCA concentration (Laihia et al., 2009) . We believe that this effect is not restricted only to bladder carcinoma cells.
Both extrinsic and intrinsic pathways of apoptosis, although differentially initiated, finally lead to activation of effector caspases (eg, caspase-3, caspase-6, and caspase-7) responsible for cleavage of several cellular proteins. Involvement of the intrinsic pathway is suggested by a study of human transitional bladder cancer cells (Peuhu E, Kaunisto A, Laihia JK, Leino L, Eriksson JE, submitted). Caspase-3 is the major effector caspase required for a typical apoptotic phenotype (Janicke et al., 1998) and can thus be considered the final determinant to fully launch the apoptotic machinery. We detected active caspase-3 at the border of the necrotic areas in both cis-UCA-treated and control tumors (Figure 4 ). This may result both from the intratumoral administration route and hypoxia-induced apoptosis. The vascularity in the tumors was typically poor. Similarly, apoptosis occurs in the penumbra of an ischemic lesion in the brain whereas necrotic cell death takes place in the core of the lesion (Friedlander, 2003) . The number of caspase-3-positive cells increased in the cis-UCA-treated tumors, and there seemed to be an association with the amount of necrosis, suggesting that Extracellular trans-UCA at pH < 5.8
Intracellular cis-UCA at pH > 7 Figure 5 . The physicochemical background of the protodynamic action of cis-UCA. (From left to right) Photo-isomerization of free (extracellular) UCA normally takes place in the acidic skin environment. At a mildly acidic pH, cis-UCA preserves one of the protons at the imidazolyl moiety. After penetration of the electroneutral molecule into the cell cytosol with a close-to-neutral pH, the proton is released and the cytosol is acidified.
cis-UCA induces cell death that is mediated, at least in part, by caspase-3. The fact that the vital areas of the cis-UCAtreated tumors were mostly negative for active caspase-3 may be understood both by the mode of action of cis-UCA and by the administration route. It should be noted that the treatment phase of the study was terminated and the tumors taken 2 days after the last intratumoral injection. During the two days, the cells in the cis-UCA-injected tumors have most likely died and are decomposing, resulting in increased necrotic areas and decreased apparent number of caspase-3-positive cells. The histological sections show the degree of caspase-3 activity at one time point only and, consequently, the number of the end-stage apoptotic cells is difficult to estimate at the immunohistochemical level. Furthermore, we do not know for how long the cells stay immunopositive or what has been their proportion in the center of the necrotic/ apoptotic areas at earlier time points.
In conclusion, this study shows a direct anticancer effect of cis-UCA on metastatic melanoma cells in culture and in established human melanoma xenografts in vivo. The data indicate that cis-UCA has a potent antiproliferative and apoptosis-inducing activity on cancer cells at the extracellular pH 6.5 but limited or no activity at pH 7.4. The modulation is related to the protodynamic action of cis-UCA in the cell cytoplasm. The intracellular acidification capability is apparently based on the pK a2 and is thus restricted to conditions where there is a pH difference between the intraand extracellular space, that is, the cytosolic pH is beyond neutral and the extracellular environment is mildly acidic. These pH conditions generally prevail in solid tumors. Finally, all of the studied treatments were well tolerated by the mice. These results provide evidence for cis-UCA as a novel and safe regimen for pharmacological intervention in cancer, including metastatic malignant melanoma.
MATERIALS AND METHODS

Urocanic acid
cis-UCA was synthesized by photo-isomerization of trans-UCA (Sigma-Aldrich, St Louis, MO and Acros Organics, Geel, Belgium) followed by anion-exchange chromatography. The purity of cis-UCA was above 99.9% by as determined by high-performance liquid chromatographic analysis, water content was 0.09% as found by the Karl Fischer method, and endotoxin concentration was below 14 IU g À1 as measured by the LAL gel clot method. cis-UCA was characterized also by IR, 1 H NMR, and 13 C NMR spectrometry, and by melting point analysis. cis-UCA was dissolved directly in the incubation media. For intratumoral injections into mice, cis-UCA was dissolved in pyrogen-free-quality phosphate-buffered saline (PBS) and water for injection, adjusted to pH 6.5, sterile filtered, and stored in pyrogen-free test tubes at 4-8 1C in the dark for less than 1 week.
Cell cultures
The transformed tumorigenic cell lines A2058 (cutaneous metastatic melanoma), HT-1080 (epithelial fibrosarcoma), and HeLa (epithelial adenocarcinoma of the cervix) were obtained from ATCC (Manassas, VA). The HT-1080 and HeLa cells were cultured in Iscove's Modified Dulbecco's Medium and the A2058 cells were cultured in DMEM (both from Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum and antibiotics (100 mg ml À1 streptomycin, 100 U ml À1 penicillin) under normal cell culture conditions in the logarithmic growth phase. In vitro experiments were performed using 15,000-75,000 viable cells in 96-well cell culture plates in a volume of 100 or 150 ml per well.
Determination of cell viability
The proliferation rate of the cells was quantified as the number of viable cells using a colorimetric method (CellTiter 96 AQueous One Solution Cell Proliferation Assay; Promega, Madison, WI) that quantifies the formation of a formazan product from the tetrazolium compound MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) in live cells. The absorbance at 490 nm was read using flat-bottomed 96-well plates at 4 hours after the addition of the assay reagent.
Annexin-V binding assay
The cells treated with UCA or CPT were trypsinized and washed with PBS and an annexin-V binding buffer consisting of 50 mM HEPES, 700 mM NaCl, and 12.5 mM CaCl 2 (pH 7.4). To each 10 5 cells in 100 ml, 8 ml of recombinant human annexin-V-FITC conjugate (Caltag, Burlingame, CA) and 12.5 mg ml À1 propidium iodide were added. After incubation at room temperature for 15 minutes, 300 ml of the binding buffer was added, and the cells were kept in an ice bath until flow cytometry analysis (FACScan; Becton Dickinson, San Jose, CA). The data were analyzed using the Cyflogic software (CyFlo, Turku, Finland).
Analysis of caspase-3 by western blotting
The proteins in 35 ml of the cell lysates described above, corresponding to about 350 mg total protein, were separated by 10% SDS-PAGE and transferred to nitrocellulose membranes. To identify active caspase-3, the blots were blocked with 5% milk in Tris-buffered saline, incubated with a rabbit mAb against cleaved caspase-3 (Asp 175; Cell Signaling, Danvers, MA), and a horseradish peroxidase-conjugated polyclonal swine anti-rabbit secondary antibody (P0217; Dako, Glostrup, Denmark). The bands were located by ECL detection (Amersham/GE Healthcare Life Sciences, Little Chalfont, Buckinghamshire, UK). In another analysis, 45 mg of protein was used on a 14% gel.
Growth of human melanoma xenografts in SCID/SCID mice
All experiments with mice were performed according to institutional guidelines and with permission of the animal test review board of the University of Turku. The SCID/SCID mice (Charles River Laboratories, Wilmington, MA) were randomly allocated into treatment groups, A, PBS (control); B, 30 mM cis-UCA; and C, 1 mM CPT (SigmaAldrich), of six animals (three males and three females) before tumor establishment. Human melanoma xenografts were established as described previously (Ahonen et al., 2002; Vähä-Koskela et al., 2006) . Briefly, 2 Â 10 6 cultured A2058 cells were injected subcutaneously into the neck of the mice. Tumors were allowed to develop for 2 weeks up to the size of a just measurable pearl. Each tumor was injected intratumorally with 50 ml of test solutions three times a week. A 27-gauge needle was used and the tumor mass was identified by palpation. After day 7 from the beginning of the injections, three 50-ml injections (150 ml in total) were administered www.jidonline.org 2437 into different areas in the tumor mass three times a week. Sixteen days after the first injection, the animals were killed with CO 2 . The tumors were collected and fixed in 3.7% formaldehyde. Tumor dimensions were measured with a caliper before each injection by a person blinded to the treatment. The planar area of the tumor was calculated as length Â width. Estimates of tumor mass were calculated according to Equation (1) (Luciani et al., 2004) 
where the measured dimensions in mm yield an approximation of tumor weight in mg. The tumor growth inhibition efficiency of the treatments was calculated according to Equation (2);
where S r represents the normalized relative tumor size (area or weight) in the control (A) or treatment group (T), and m1-m8 are the (eight) time points of measurement during the 16-day treatment period. One mouse from groups A and C was killed before the end of the experiment because of poor development of the tumor (no measurable tumor at day 0). One animal in group B was killed prematurely after it had severely scratched the tumor. The removed animals were females. The data from these animals were not included in the analyses.
Immunohistochemistry
The fixed tumors were embedded in paraffin. Sections of 3 mm thickness were cut and paraffin was removed with xylene and alcohol. The samples were boiled twice in a microwave oven in 10 mM citrate buffer (pH 6.0) for 7 minutes. Ki-67 staining was performed using the Techmate immunostaining system (Bio Tek Solutions, Santa Barbara, CA) using a rabbit anti-Ki-67 antibody (M7420; Dako) diluted 1:100 in 1% BSA in PBS. A rabbit mAb detecting cleaved caspase-3 (Asp 175; Cell Signaling) was diluted 1:200 in 1% BSA in PBS, and the primary immunoreaction was localized by using a Vectastain avidin-biotin complex peroxidase (ABC) kit (Vector, Burlingame, CA). The sections were counterstained with hematoxylin. The amount of necrotic tumor tissue was determined from micrographs taken with an objective magnification factor of 2. The micrographs were divided into 540 equal areas and the percentage of necrotic areas was counted using Corel Photo-paint 10. The percentages of Ki-67-positive tumor cells were estimated from the areas containing the highest proportion of immunopositive cells in each sample. The estimation was made by two skilled persons blinded to the group data.
Statistical analysis
Statistical significance of differences in the data from the viability assays and tumor size measurements was calculated by two-way Student's t-test. Statistical significance of differences in the number of Ki-67-positive cells and in the percentage of necrosis in the tumor sections was evaluated by one-way analysis of variance with Tukey-Kramer adjustment using the SAS program. The alpha level 0.05 was used in all comparisons.
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